January 4, 2024

3 Minutes
Medicine

MediLink Therapeutics and Roche Announces Worldwide Collaboration and License Agreement

MediLink Therapeutics have announced that it has entered into a worldwide collaboration and license agreement with Roche on the development of a next-generation antibody-drug conjugate candidate YL211, targeting c-Mesenchymal epithelial transition factor (c-Met) against solid tumours. YL211...
Read More